Skip to main content

Month: December 2020

PATIKSLINIMAS: Pranešimas apie AUGA group, AB tarpinę finansinę informaciją už 9 mėn. laikotarpį, pasibaigusį 2020 m. rugsėjo 30 d.

Patikslinimas: Patikslinti duomenys pranešime (Grupės EBITDA rodiklis), patikslinimas atliktas abiejomis kalbomis.AUGA group, AB ir jos dukterinės bendrovės (toliau – Grupė) toliau didino pardavimus visuose verslo segmentuose ir gerino pelno rodiklius.Per 2020 m. 9 mėnesius Grupės pardavimo pajamos siekė 62,38 mln. Eur ir buvo 33 proc. didesnės nei praėjusiais metais, kuomet pajamos siekė 47,05 mln. Eur. Grupės bendrasis pelnas per 9 mėnesių periodą pasiekė 11,88 mln. Eur ir buvo 48 proc. didesnis, lyginant su ankstesniais metais, kai bendrasis pelnas siekė 8,00 mln. Eur. Per tą patį 2020 m. periodą Grupė uždirbo 0,44 mln. Eur grynojo pelno, palyginus su 1,28 mln. Eur nuostoliu metais prieš tai.Pagal AUGA group, AB duomenis, Grupės EBITDA per tris 2020 m. ketvirčius siekė 15,94 mln. Eur ir buvo 28 proc. didesnė nei tuo pačiu laikotarpiu...

Continue reading

Global Regenerative Medicine Market to Rise Impressively at 26.1% CAGR and Hit USD 151,949.5 Million by 2026; Integra’s Latest Product Offerings to Enable Growth, says Fortune Business Insights™

Pune, India, Dec. 01, 2020 (GLOBE NEWSWIRE) — The global regenerative medicine market size is likely to expand considerably in the coming years due to growing applications in the treatment of chronic diseases. The market was valued at US$ 23,841.5 Million in 2018. Fortune Business Insights states that the market will reach US$ 151,949.5 Million by the end of 2026, thereby exhibiting a CAGR of 26.1%. North America generated maximum revenue of US$ 9,128.2 Million in 2018 and is expected to dominate the global regenerative medicine market throughout the forecast period. Due to presence of substantial number of key market players based in U.S., presence of research institutes involved in development of novel therapeutics and availability of advanced technologies are attributive to the high number of clinical trials in North America.Key...

Continue reading

Global Home Infusion Therapy Market to Exhibit 2.2% CAGR and Hit USD 86.89 Billion by 2027; Rise in Adoption of Advanced Technological Devices for Home Care to Drive the Market in North America, says Fortune Business Insights™

Pune, India, Dec. 01, 2020 (GLOBE NEWSWIRE) — The global home infusion therapy market size is likely to USD 86.89 billion by the end of 2027 owing to the increasing adoption of home medical services worldwide. In a home infusion therapy setting, a patient receives all medical assistance at home including drugs and biologics via a subcutaneous or an intravenous administrative route. The value of this market was USD 27.25 billion in 2019 and is expected to grow at a CAGR of 2.2% between 2020 and 2027. North America emerged at the top with a revenue of USD 10.53 billion in 2019. The growth of this region is attributable to the development of delivery devices for home medication and its increasing adoption.KEY INDUSTRY DEVELOPMENTS:December 2019 –   Optum, Inc. announced the collaboration with Diplomat, a provider of specialty pharmacy...

Continue reading

MarketAxess Completes Acquisition of Regulatory Reporting Hub From Deutsche Börse Group

NEW YORK and AMSTERDAM, Dec. 01, 2020 (GLOBE NEWSWIRE) — MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, has completed its previously announced acquisition of Regulatory Reporting Hub, the regulatory reporting business of Deutsche Börse Group. MarketAxess acquired the business through Trax NL B.V., its wholly owned subsidiary in the Netherlands, on 30 November 2020.Christophe Roupie, Head of EMEA and APAC at MarketAxess, commented: “We’re delighted to welcome clients of the Regulatory Reporting Hub to MarketAxess. This acquisition is a firm demonstration of our long-term commitment to building our regulatory reporting infrastructure across Europe. It will help us...

Continue reading

Sampo plc announces indicative results of its cash tender offers

NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OR THE DISTRICT OF COLUMBIA OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENTSAMPO PLC                 STOCK EXCHANGE RELEASE 1 December 2020 at 9:05 amSampo plc announces indicative results of its cash tender offers in respect of its outstanding EUR 500,000,000 1.50 per cent. Notes due 16 September 2021, SEK 700,000,000 0.875 per cent. Notes due 23 May 2022, SEK 1,300,000,000 Floating Rate Notes due 23 May 2022, EUR 750,000,000 1.00 per cent. Notes due 18 September 2023 and EUR 500,000,000 1.250 per cent....

Continue reading

Sampo Oyj ilmoittaa alustavat tulokset käteisostotarjouksistaan

EI LEVITETTÄVÄKSI TAI JULKISTETTAVAKSI, SUORAAN TAI VÄLILLISESTI, YHDYSVALLOISSA, SEN ALUEELLA TAI TERRITORIOISSA (MUKAAN LUKIEN PUERTO RICO, YHDYSVALTAIN NEITSYTSAARET, GUAM, AMERIKAN SAMOA, WAKE ISLAND JA POHJOIS-MARIAANIT), OSAVALTIOISSA TAI COLUMBIAN LIITTOPIIRISSÄ, TAI LAINKÄYTTÖALUEILLA, JOISSA TÄMÄN TIEDOTTEEN JULKAISEMINEN TAI LEVITTÄMINEN ON LAINVASTAISTA, TAI HENKILÖILLE, JOTKA OVAT TAI JOIDEN ASUINPAIKKA ON YHDYSVALLOISSA TAI TÄLLAISILLA LAINKÄYTTÖALUEILLASAMPO OYJ                             PÖRSSITIEDOTE         1.12.2020 klo 9.05Sampo Oyj ilmoittaa alustavat tulokset käteisostotarjouksistaan, jotka koskevat ulkona olevia 16.9.2021 erääntyviä 500 000 000 euron 1,50 prosentin velkakirjoja, 23.5.2022 erääntyviä 700 000 000 Ruotsin kruunun 0,875 prosentin velkakirjoja, 23.5.2022 erääntyviä 1 300 000 000 Ruotsin kruunun vaihtuvakorkoisia...

Continue reading

Europe Ball Bearings Market to Hit USD 5.50 billion by 2027; Rising Demand for Long-lasting Industrial Machine Components to Aid Market Growth: Fortune Business Insights™

Pune, Dec. 01, 2020 (GLOBE NEWSWIRE) — The Europe ball bearings market size is projected to reach USD 5.50 billion by 2027, exhibiting a CAGR of 1.9% during the forecast period. Introduction of Industry 4.0 technologies in the production of bearings will create huge opportunities in the market, observes Fortune Business Insights™ in its report, titled “Europe Ball Bearings Market Size, Share & COVID-19 Impact Analysis, By Product Type (Self Aligning Ball Bearings, Deep Grove Ball Bearings, Angular Contact Ball Bearings & Others), By Application (Automotive, Industrial machinery, Mining & Construction, Medical & Others), and Country Forecast, 2020-2027”. Smart manufacturing powered by Industry 4.0 technologies such as artificial intelligence (AI), machine learning (ML), and the internet of things (IoT) is gaining...

Continue reading

Transocean Ltd. Announces Amendments to Certain Financing Documents and Internal Reorganization Transactions to Resolve Allegations Contained in Purported Notices of Default

STEINHAUSEN, Switzerland, Dec. 01, 2020 (GLOBE NEWSWIRE) — Transocean Ltd. (NYSE: RIG) announced today that it, Transocean Inc. (together with Transocean Ltd., the “Company”) and certain of its subsidiaries executed amendments to certain of their financing documents and implemented certain internal reorganization transactions to resolve the allegations contained in the previously disclosed notices of alleged default (the “Notices”) with respect to Transocean Inc.’s 7.25% Senior Notes due 2025 (the “2025 Guaranteed Notes”) and 8.00% Senior Notes due 2027 (the “2027 Guaranteed Notes”).Immediately following such transactions and amendments (the “Transactions”), the Transocean Mid Holdings Entities (as defined below) have been eliminated and the Transocean Holdings Entities (as defined below) directly hold the equity interests of the...

Continue reading

Junshi Biosciences Announces Dosing of First Patient in Phase I Study of Anti-TROP2 Antibody -TUB196 Conjugate

SHANGHAI, China, Dec. 01, 2020 (GLOBE NEWSWIRE) — Junshi Biosciences (HKEX: 1877; SSE: 688180), an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies, is pleased to announce that the Phase I clinical study (NCT04601285) of a recombinant humanized anti-TROP2 monoclonal antibody – Tub196 conjugate (JS108), has completed the dosing of the first patient.JS108 is a recombinant humanized anti-TROP2 monoclonal antibody – Tub196 Conjugate. TROP2 is an important receptor expressed at high level in a variety of solid tumors (including breast cancer, gastric cancer, non-small cell lung cancer, small cell lung cancer, colon cancer and pancreatic cancer) , implicated in promoting tumor cell proliferation, tissue invasion, and metastasis. Overexpression of TROP2...

Continue reading

Clean Power Provides Update on the Development of Its PowerTap Investment

VANCOUVER, British Columbia, Dec. 01, 2020 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (CSE: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). The Company is pleased to provide an update on the activities of PowerTap Hydrogen Fueling Corp. (“PowerTap”), the company’s previously announced investment. PowerTap is in the process of completing its 3rd generation design of its patented onsite hydrogen production and dispensing technology for the North American hydrogen vehicle market.As PowerTap looks to roll out the 3rd generation of its onsite hydrogen production and dispensing technology for hydrogen trucks and cars, PowerTap believes that its new modular design of the units has distinct advantages over the previous two generations of PowerTap units installed in the United States and other hydrogen fueling technologies....

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.